50593-91-4

Basic information

• Product Name: METHYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97
• Synonyms: Methyl 5-bromo-2-(methylsulfanyl)-4-pyrimidinecarboxylate;METHYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97;Methyl 5-bromo-2-(methylthio)pyrimidine-4-carboxylate ,97%;methyl 5-bromo-2-(methylthio)pyrimidine-4-carboxylate;Methyl 5-BroMo-2-(Methylthio)-4-pyriMidinecarboxylate;THYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97;4-PyriMidinecarboxylic acid, 5-broMo-2-(Methylthio)-, Methyl ester;5-Bromo-2-(methylsulfanyl)pyrimidine-4-carboxylic acid methyl ester
• CAS NO: 50593-91-4
• Molecular Formula: C₇H₇BrN₂O₂S
• Molecular Weight: 263.11168
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 50593-91-4.mol
• Article Data: 18

Chemical Properties

• Melting Point: 67 °C
• Boiling Point: 348.7±22.0 °C(Predicted)
• Appearance: Pale yellow/Solid
• Density: 1.69±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -2.91±0.29(Predicted)
• Water Solubility: Slightly soluble in water (0.42 g/L).
• CAS DataBase Reference: METHYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97(50593-91-4)
• EPA Substance Registry System: METHYL 5-BROMO-2-(METHYLSULFANYL)-4-PYRIMIDINECARBOXYLATE, 97(50593-91-4)

Safety Data

• Hazard Codes: Xi
• Statements: 43-36/37/38-20/21/22
• Safety Statements: 36/37-36/37/39-26-22
• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 50593-91-4(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

Upstream product

• 50593-92-5 5-bromo-2-methylsulfanyl-pyrimidine-4-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 75-36-5 acetyl chloride 
• 67-56-1 methanol 

Downstream Products

• 945913-52-0 2-methylsulfanyl-5-(2-methylphenyl)ethynylpyrimidine-4-carboxylic acid methyl ester 
• 1286255-06-8 C₂₀H₁₅ClN₄O₂S 
• 1286255-08-0 C₂₀H₁₅FN₄O₂S 
• 1286255-09-1 C₂₂H₁₆N₄O₂S 
• 1286255-10-4 C₂₁H₁₅F₃N₄O₂S 
• 1186037-06-8 C₂₁H₁₈N₄O₄S 
• 1578244-15-1 N⁸-cyclopropylmethyl-N²-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidine-2,8-diamine 
• 1578244-16-2 N₈-cyclopentyl-N₂-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N₈-methylpyrido[3,4-d]pyrimidine-2,8-diamine 
• 1578244-17-3 N₈-isopentyl-N₂-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidine-2,8-diamine 
• 1578244-20-8 8-(3,3-difluoroazetidin-1-yl)-N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)pyrido[3,4-d]pyrimidin-2-amine 
• 1578244-21-9 N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(2-methylpyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-2-amine 
• 1578244-23-1 N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(6-azaspiro[3.4]octan-6-yl)pyrido[3,4-d]pyrimidin-2-amine 
• 1578244-24-2 N-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-8-(3-methoxyazetidin-1-yl)pyrido[3,4-d]pyrimidin-2-amine 
• 1578244-26-4 N²-(2-methoxy-4-(1-methyl-1H-pyrazol-4-yl)phenyl)-N⁸-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-d]pyrimidine-2,8-diamine 

Relevant articles and documents

NOVEL PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING CANCER, COMPRISING SAME

The present disclosure relates to a pyrido[3,4-d]pyrimidin-8-one derivative compound exhibiting excellent anti-proliferative effects against cancer cells, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a stereoisomer thereof, a production method therefor, a pharmaceutical composition for preventing, alleviating or treating cancer metastasis and proliferative disease containing the same as an active ingredient, and an anticancer composition against cancer cells. The compound exhibits excellent cancer cell inhibitory activity and anti-proliferative effects, and thus is effective in inhibiting cancer cells, preventing cancer metastasis and proliferative diseases or treating cancer.

CRYSTAL OF PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE OR SOLVATE THEREOF

Provided is a crystal of a novel pyrido[3, 4-d]pyrimidine derivative having excellent CDK 4/6 inhibitory activity. A crystal of a compound represented by formula (I). In the formula, R1 represents a hydrogen atom or a C1-3 alkyl group; R2 represents a hydrogen atom or an oxo group; L represents a single bond or a C1-3 alkylene group; and X represents CH or N.

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development

Inhibition of embryonic ectoderm development (EED) is a new cancer therapeutic strategy. Herein, we report our discovery of EEDi-5285 as an exceptionally potent, efficacious, and orally active EED inhibitor. EEDi-5285 binds to the EED protein with an IC50 value of 0.2 nM and inhibits cell growth with IC50 values of 20 pM and 0.5 nM in the Pfeiffer and KARPAS422 lymphoma cell lines, respectively, carrying an EZH2 mutation. EEDi-5285 is approximately 100 times more potent than EED226 in binding to EED and >300 times more potent than EED226 in inhibition of cell growth in the KARPAS422 cell line. EEDi-5285 has excellent pharmacokinetics and achieves complete and durable tumor regression in the KARPAS422 xenograft model in mice with oral administration. The cocrystal structure of EEDi-5285 in a complex with EED defines the precise structural basis for their high binding affinity. EEDi-5285 is the most potent and efficacious EED inhibitor reported to date.